GSK, Vi­iV of­fer sneak peek of PhI­II da­ta on in-house two-drug HIV com­bo, tout­ing non-in­fe­ri­or­i­ty

Press­ing on with its am­bi­tious goal to out­shine Gilead in the HIV space, Glax­o­SmithK­line is now armed with pos­i­tive da­ta on its two-drug reg­i­men from a pair of Phase III stud­ies — if we take their word for it.

Vi­iV Health­care — GSK’s ded­i­cat­ed HIV arm — re­port­ed overnight that GEM­I­NI-1 and GEM­I­NI-2 met their pri­ma­ry end­point based on plas­ma HIV-1 RNA <50 copies per mil­li­l­itre (c/mL) at week 48, es­sen­tial­ly show­ing non-in­fe­ri­or­i­ty of do­lute­gravir and lamivu­dine com­pared to the stan­dard three-drug reg­i­men. In ad­di­tion to safe­ty in­for­ma­tion, that’s as much as GSK is will­ing to di­vulge at the mo­ment, choos­ing to save the de­tails for an up­com­ing med­ical con­fer­ence.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER